Purification of heat shock protein 70-associated tumor peptides and its antitumor immunity on hepatoma in mice

Table 1 Comparison of survival time of tumor-bearing mice after immunized by HSP70-peptide complexes

Groups		Sex	No. of tumor-bearing/No. of mice challenged	Survival days of tumor-bearing (mean ± SD)	Extended survival rate (%)
			HSP70	300 μg/kg	Female	2/6	48.0 ± 8.5ad	67.4bd
Male	6/6	31.0 ± 13.2			49.7c
	600 μg/kg	Female	1/6	33
		Male	6/6	30.7 ± 12.7	48.4c
S-HCaF		Female	5/6	59.2 ± 10.0bd	106.5bd
		Male	6/6	20.3 ± 0.9	-2.0
S-HC		Female	6/6	24.0 ± 5.8	-16.3
		Male	6/6	18.5 ± 0.6	-10.5
PBS		Female	6/6	28.7 ± 11.6
		Male	6/6	20.7 ± 6.1

^aP < 0.05, vs PBS;

^bP < 0.01, vs PBS;

^cP < 0.01, vs S-HC;

^dP < 0.05, vs S-HC. Extended survival rate = [(MST of experimental group - MST of control group)/MST of control group] × 100%

Table 2 Comparison of tumor growth in mice immunized with HSP70-peptide complexes

Groups		Sex	No. of tumor-	10 days after HCaf challenge		15 days after HCaF challenge
				Size of tumor (mm3)	Inhibition rate (%)	Size of tumor (mm3)	Inhibition rate (%)
			bearing mice
HSP70	300 μg/kg	Female	2	0.88bc	97.0ac	6.66bd	98.5ad
		Male	6	61.98bd	80.2bd	384.77bc	83.2bc
	600 μg/kg	Female	1	0.45	98.4	5.74
		Male	6	64.49b	79.4bd	515.10bc	77.6bc
S-HCaF		Female	5	3.09bc	89.2bc	10.21bc	97.7bc
		Male	6	24.27bd	92.2bd	501.55b	78.2bd
S-HC		Female	6	30.00	-4.5	402.17	8.2
		Male	6	204.89	34.5	1554.30	32.3
PBS		Female	6	28.70		438.17
		Male	6	312.83		2295.52

^aP < 0.05, vs PBS;

^bP < 0.01, vs PBS;

^cP < 0.01, vs S-HC;

^dP < 0.05, vs S-HC. Inhibition rate (%)=1 - [(Tumor size of experimental group/Tumor size of control group(PBS)) × 100%]

Table 3 Comparison of tumor weight and spleen weight after tumor-bearing mice death (mean ± SD)

Groups		Female			Male
		No. of tumor-bearing mice	Tumor	Spleen	No. of tumor-bearing mice	Tumor	Spleen
			wt. (g)	wt. (g)		wt. (g)	wt. (g)
HSP70	300 μg/kg	2	14.40 ± 6.22bce	0.93 ± 0.18bde	6	7.06 ± 2.59	0.19 ± 0.04
	600 μg/kg	1	6.5	0.4	6	7.51 ± 2.33	0.20 ± 0.11
S-HCaF		6	8.68 ± 1.65a	0.53 ± 0.22be	6	5.06 ± 0.71	0.24 ± 0.10
S-HC		5	4.72 ± 1.65	0.17 ± 0.08	6	4.98 ± 1.04	0.14 ± 0.02
PBS		6	6.78 ± 1.34	0.25 ± 0.06	6	6.30 ± 2.18	0.12 ± 0.07

^aP < 0.05, vs S-HC;

^bP < 0.01, vs S-HC;

^cP < 0.05, vs S-HCaF;

^dP < 0.01, vs S-HCaF;

^eP < 0.01, vs PBS.

Table 4 Adoptive immunoprotective effect against HCaF challenge elicited by ISC transfer

Group	Survival rate (%)		Survival days of	Extended	Tumor wt. (g)	Spleen wt.(g)
	(No. of death/No. of mice challenged)		tumor-bearing mice (mean ± SD)	survival rate (%)	(mean ± SD)	(mean ± SD)
ISC	75	(2/8)a	50.5 ± 9.2b	71.0b	14.92 ± 0.42bc	0.39 ± 0.01bc
SC	0	(8/8)	36.8 ± 12.9	24.6	7.73 ± 2.14	0.18 ± 0.05
Chal. control	0	(8/8)	29.5 ± 3.9	0	7.35 ± 1.16	0.21 ± 0.05

^aP < 0.05, vs chal. Control;

^bP < 0.01, vs chal. Control;

^cP < 0.01, vs SC.